JP2021520232A5 - - Google Patents

Info

Publication number
JP2021520232A5
JP2021520232A5 JP2021504131A JP2021504131A JP2021520232A5 JP 2021520232 A5 JP2021520232 A5 JP 2021520232A5 JP 2021504131 A JP2021504131 A JP 2021504131A JP 2021504131 A JP2021504131 A JP 2021504131A JP 2021520232 A5 JP2021520232 A5 JP 2021520232A5
Authority
JP
Japan
Prior art keywords
sequence encoding
sequence
cells
item
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021504131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520232A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/026062 external-priority patent/WO2019195727A1/en
Publication of JP2021520232A publication Critical patent/JP2021520232A/ja
Publication of JP2021520232A5 publication Critical patent/JP2021520232A5/ja
Withdrawn legal-status Critical Current

Links

JP2021504131A 2018-04-05 2019-04-05 黄斑ジストロフィーを処置するための組成物及び方法 Withdrawn JP2021520232A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862653131P 2018-04-05 2018-04-05
US62/653,131 2018-04-05
PCT/US2019/026062 WO2019195727A1 (en) 2018-04-05 2019-04-05 Compositions and methods for treating macular dystrophy

Publications (2)

Publication Number Publication Date
JP2021520232A JP2021520232A (ja) 2021-08-19
JP2021520232A5 true JP2021520232A5 (enExample) 2022-04-12

Family

ID=66223872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021504131A Withdrawn JP2021520232A (ja) 2018-04-05 2019-04-05 黄斑ジストロフィーを処置するための組成物及び方法

Country Status (21)

Country Link
US (2) US20190307900A1 (enExample)
EP (1) EP3775233A1 (enExample)
JP (1) JP2021520232A (enExample)
KR (1) KR20210005040A (enExample)
CN (1) CN113056561A (enExample)
AU (1) AU2019247864A1 (enExample)
BR (1) BR112020020204A2 (enExample)
CA (1) CA3096088A1 (enExample)
CL (1) CL2020002561A1 (enExample)
CO (1) CO2020013690A2 (enExample)
EA (1) EA202092069A1 (enExample)
IL (1) IL277779A (enExample)
JO (1) JOP20200253A1 (enExample)
MA (1) MA52199A (enExample)
MX (1) MX2020010477A (enExample)
PE (1) PE20210918A1 (enExample)
PH (1) PH12020551641A1 (enExample)
RU (1) RU2020132890A (enExample)
SG (1) SG11202009759SA (enExample)
TW (1) TW202003052A (enExample)
WO (1) WO2019195727A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3112883A1 (en) * 2018-10-25 2020-04-30 Baxalta Incorporated Aav triple-plasmid system
US20220089670A1 (en) * 2018-12-28 2022-03-24 University Of Rochester Gene Therapy for BEST1 Dominant Mutations
IL295673A (en) * 2020-02-28 2022-10-01 Univ Pennsylvania Treatment of autosomal dominant strophin diseases and methods of their evaluation
CN111849998A (zh) * 2020-07-29 2020-10-30 武汉纽福斯生物科技有限公司 编码人卵黄状黄斑病蛋白1的核酸分子及其应用
WO2024064608A2 (en) * 2022-09-20 2024-03-28 Intergalactic Therapeutics, Inc. Best1 vectors and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2307551T3 (en) * 2008-06-18 2017-03-20 Oxford Biomedica (Uk) Ltd CLEANING RETROVIRAL VECTORS
US9163259B2 (en) * 2012-05-04 2015-10-20 Novartis Ag Viral vectors for the treatment of retinal dystrophy
WO2015075154A2 (en) * 2013-11-20 2015-05-28 Fondazione Telethon Artificial dna-binding proteins and uses thereof
KR102281881B1 (ko) * 2013-12-06 2021-07-27 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) 대상체의 망막 색소 상피에서 목적 폴리뉴클레오티드를 발현시키기 위한 방법 및 약학적 조성물
GB201322798D0 (en) * 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
SI3265571T1 (sl) * 2015-03-03 2022-10-28 Fondazione Telethon Več vektorski sistem in njegove uporabe
WO2017083722A1 (en) * 2015-11-11 2017-05-18 Greenberg Kenneth P Crispr compositions and methods of using the same for gene therapy

Similar Documents

Publication Publication Date Title
JP2021520232A5 (enExample)
US12383587B2 (en) AAV triple-plasmid system
JP2022535749A5 (enExample)
JP2022508182A5 (enExample)
JP2022549380A5 (enExample)
IL278213B1 (en) A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd)
US20040142416A1 (en) Treatment for phenylketonuria
JP7541027B2 (ja) 筋肉発現のためのハイブリッドプロモーター
WO2016100575A1 (en) Gene therapy for juvenile batten disease
US20070243168A1 (en) Minigene expression cassette
JP2024099770A5 (enExample)
JP2021533805A5 (enExample)
JP2022524434A5 (enExample)
JP2022551744A5 (enExample)
WO2020142714A1 (en) Aav expression cassette and aav vectors comprising the same
RU2020132890A (ru) Композиции и способы лечения макулярной дистрофии
JP2021534766A5 (enExample)
JP2023542131A5 (enExample)
US20240218397A1 (en) Novel aav vectors and methods and uses thereof
CN113891712A (zh) 用于晚期婴儿神经元蜡样脂褐质沉积症2型的aav载体治疗方法
CN120457199A (zh) 截短的atp7b及其用途
JP2025534666A (ja) 操作された核酸調節エレメントならびにその使用方法
JP2025515030A5 (enExample)
KR102874560B1 (ko) 아데노연관바이러스 변이체
JP2023504201A5 (enExample)